BioMarin Pharmaceutical (BMRN) announced that the company has initiated a legal action against Ascendis Pharma (ASND) for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court in Munich, Germany. The patent covers long-acting variants of C-Type Natriuretic Peptide. The legal action, which would result in a decision in the next 12-15 months, is based on BioMarin’s belief that Ascendis’ TransCon CNP investigational product and its development program in Germany and elsewhere in Europe infringe BioMarin’s patent. The BioMarin patent was confirmed by the European Patent Office’s Opposition Division in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- TD Cowen ‘disappointed’ Pfizer ended Sangamo collaboration
- Penny Stock Sangamo (SGMO) Nosedives as Pfizer Terminates Partnership
- Soros boosts stake in AstraZeneca, exits Apple position
- Wolfe Research starts BioMarin at Outperform given its blockbuster with Voxzogo
- BioMarin initiated with an Outperform at Wolfe Research
Questions or Comments about the article? Write to editor@tipranks.com